The efficacy of oncolytic viruses (OVs), such as reovirus, is dictated by host immune responses, including those mediated by the pro- versus anti-inflammatory macrophages. As such, a detailed understanding of the interaction between reovirus and different macrophage types is critical for therapeutic efficacy. To explore reovirus-macrophage interactions, we performed tandem mass tag (TMT)-based quantitative temporal proteomics on mouse bone marrow-derived macrophages (BMMs) generated with two cytokines, macrophage colony stimulating factor (M-CSF) and granulocytic-macrophage colony stimulating factor (GM-CSF), representing anti- and proinflammatory macrophages, respectively. We quantified 6863 proteins across five time points in duplicate, comparing M-CSF (M-BMM) and GM-CSF (GM-BMM) in response to OV. We find that GM-BMMs have lower expression of key intrinsic proteins that facilitate an antiviral immune response, express higher levels of reovirus receptor protein JAM-A, and are more susceptible to oncolytic reovirus infection compared to M-BMMs. Interestingly, although M-BMMs are less susceptible to reovirus infection and subsequent cell death, they initiate an antireovirus adaptive T cell immune response comparable to that of GM-BMMs. Taken together, these data describe distinct proteome differences between these two macrophage populations in terms of their ability to mount antiviral immune responses.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294930PMC
http://dx.doi.org/10.1021/acs.jproteome.9b00583DOI Listing

Publication Analysis

Top Keywords

oncolytic reovirus
8
bone marrow-derived
8
immune responses
8
colony stimulating
8
stimulating factor
8
antiviral immune
8
immune response
8
reovirus infection
8
reovirus
6
quantitative proteome
4

Similar Publications

This study evaluates the oncolytic potential of the Moscow strain of reovirus against human metastatic melanoma and glioblastoma cells. The Moscow strain effectively infects and replicates within human melanoma cell lines and primary glioblastoma cells, while sparing non-malignant human cells. Infection leads to the selective destruction of neoplastic cells, mediated by functional viral replication.

View Article and Find Full Text PDF
Article Synopsis
  • - Irinotecan is an ineffective standalone treatment for colorectal cancer, but combining it with Metformin and oncolytic Reovirus-infected secretome shows promise in boosting anti-tumor activity.
  • - The study analyzed the effects of these combinations on murine colorectal cancer cells (CT26) and demonstrated significantly lower cell viability and higher apoptosis rates with the triple combination over other treatments.
  • - Results indicate that using Reovirus-infected secretome alongside Metformin and Irinotecan produces a stronger synergistic effect for inducing cancer cell death compared to other combinations tested.
View Article and Find Full Text PDF

Oncolytic virotherapy represents an innovative and promising approach for the treatment of cancer, including multiple myeloma (MM), a currently incurable plasma cell (PC) neoplasm. Despite the advances that new therapies, particularly immunotherapy, have been made, relapses still occur in MM patients, highlighting the medical need for new treatment options. Oncolytic viruses (OVs) preferentially infect and destroy cancer cells, exerting a direct and/or indirect cytopathic effect, combined with a modulation of the tumor microenvironment leading to an activation of the immune system.

View Article and Find Full Text PDF

Urinary tumors pose a significant health threat because of their high prevalence and recurrence rates. Despite the availability of various treatment options, many patients poorly respond to traditional therapies, highlighting the urgent need for alternative approaches. Oncolytic viruses are promising therapeutic agents.

View Article and Find Full Text PDF

Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer.

Nat Commun

October 2024

Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Gyeonggi-do, Republic of Korea.

Article Synopsis
  • - The study explores the use of an oncolytic reovirus (RC402) administered orally to stimulate antitumor immunity in advanced cancers, showing no major side effects while effectively reducing tumor lesions.
  • - The orally delivered reovirus interacts with the immune system, enhancing antibody production, reshaping the gut microbiome, and promoting immune activation, though it doesn't directly infect tumors outside the gastrointestinal tract.
  • - Combining oral reovirus treatment with immune checkpoint inhibitors (like αPD-1 and αCTLA-4) significantly enhances tumor regression and establishes lasting immune memory, highlighting its potential as an effective immunotherapy approach in cancer treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!